BDTX
BLACK DIAMOND THERAPEUTICS, INC.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $4.64 | $2.58 | -44% |
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $5.00 | $2.58 | -48% |
| Two Sigma Investments re-entered | Q3 2024(8Q snapshot) | 7Q | $5.00 | $2.58 | -48% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $5.00 | $2.58 | -48% |
| Point72 Asset Management re-entered | Q4 2024(8Q snapshot) | 6Q | $2.85 | $2.58 | -9% |
| D.E. Shaw | Q1 2025(8Q snapshot) | 5Q | $2.37 | $2.58 | +9% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| AQR Capital Management 2× in & out | Q2 2025 | Q1 2026 | → $2.23 | +16% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Black Diamond Therapeutics, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Mar 20, 2026 — the most recent Form 4 on file — not from today.
- Form 40001193125-26-117938Mar 20, 2026
- Form 40002018686-26-000002Mar 20, 2026
- Form 40001895913-26-000002Jan 23, 2026
- Form 40001637054-26-000002Jan 23, 2026
- Form 40001880385-26-000002Jan 23, 2026
- Form 40001686295-26-000002Jan 23, 2026
- Form 40001706847-26-000002Jan 23, 2026
- Form 40001193125-25-319303Dec 15, 2025
- Form 40002018686-25-000007Dec 15, 2025
- Form 40001193125-25-211678Sep 22, 2025
- Form 40002018686-25-000004Sep 22, 2025
- Form 40000950170-25-088527Jun 20, 2025
- Form 40001415889-25-017821Jun 20, 2025
- Form 40000950170-25-085676Jun 12, 2025
- Form 40001415889-25-017058Jun 12, 2025
Fundamentals
XBRL · BLACK DIAMOND THERAPEUTICS, INC.Annual figures sourced directly from BLACK DIAMOND THERAPEUTICS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Black Diamond Therapeutics, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KFORM 8-KMay 21, 2026
- 10-QQuarterly reportMay 7, 2026
- 8-KMaterial eventMay 7, 2026
- DEF 14AProxy statementApr 29, 2026
- 10-KAnnual reportMar 16, 2026
- 8-KMaterial eventMar 16, 2026
- 8-KFORM 8-KDec 3, 2025
- S-3Registration (shelf)Nov 13, 2025
- 10-QQuarterly reportNov 6, 2025
- 8-KMaterial eventNov 6, 2025
- 10-QQuarterly reportAug 7, 2025
- 8-KMaterial eventAug 7, 2025
- 8-KFORM 8-KJun 12, 2025
- 10-QQuarterly reportMay 12, 2025
- 8-KMaterial eventMay 12, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Two Sigma Investments | Q2 2026 | open | $2.75 | $2.58 | -6% |
| Citadel Advisors | Q1 2026 | open | $2.23 | $2.58 | +16% |
| Point72 Asset Management | Q1 2026 | open | $2.23 | $2.58 | +16% |
| Citadel Advisors | Q3 2025 | Q4 2025 | $2.79 | $4.01 | +44% |
| AQR Capital Management | Q2 2025 | Q1 2026 | $1.93 | $2.23 | +16% |
| D.E. Shaw | Q1 2025 | open | $2.37 | $2.58 | +9% |
| AQR Capital Management | Q4 2024 | Q1 2025 | $2.85 | $2.37 | -17% |
| Point72 Asset Management | Q4 2024 | Q1 2025 | $2.85 | $2.37 | -17% |
| Citadel Advisors | Q3 2024 | Q1 2025 | $5.00 | $2.37 | -53% |
| Two Sigma Investments | Q3 2024 | Q1 2025 | $5.00 | $2.37 | -53% |
| Millennium Management | Q3 2024 | open | $5.00 | $2.58 | -48% |
| Renaissance Technologies | Q3 2024 | open | $4.64 | $2.58 | -44% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.